3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Multiple Myeloma
2
Lymphoma
2
Sarcoma, Alveolar Soft Part
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Nausea and Vomiting
1
Philadelphia Chromosome
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Leukemia, B-Cell
1
Leukemia
1
Hematologic Neoplasms
1
Colorectal Neoplasms
1
Chondrosarcoma
1
Burkitt Lymphoma
1
Advanced Solid Tumors
1
Interventions
durvalumab
7
Carboplatin
7
Docetaxel
6
Paclitaxel
5
Nivolumab
5
talazoparib
4
linifanib
4
Cisplatin
4
trifluridine tipiracil drug combination
3
tremelimumab
3
tislelizumab
3
depatuxizumab
3
ST 1481
3
S 1 (combination)
3
Panobinostat
3
Gemcitabine
3
zimberelimab
2
toripalimab
2
olaparib
2
motesanib diphosphate
2
mogamulizumab
2
TAS-114
2
Sorafenib
2
Rifampin
2
PM 01183
2
Oxaliplatin
2
MLN 8237
2
Itraconazole
2
Injections
2
Erlotinib Hydrochloride
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Advanced Solid Tumors
×
Antiemetics
×
Clear all
NCT06242691
2026-06-05
MK-1200-002
Merck Sharp & Dohme LLC
Phase 1/2
Completed
13 enrolled
21 charts